An open and free-of-charge-workshop entitled "CHEMORESISTANCE: a major treatment failure in oncology" was held at Istituto Nazionale dei Tumori (INT), in Milan, January 21, 2009. Biological and clinical aspects were covered and the level was general oncology.

The list of speakers included many prominent researchers in the field and there were 93 registered participants. All were welcomed to INT by the General Director Marco Pierotti, who pointed out the relevance of studying chemoresistance and also the importance of disseminating new discoveries. Johan Hansson (Karolinska Institutet) gave a general overview of the topic and of CHEMORES. Thomas Tursz (Institut Gustave Roussy) discussed the need for new classifications and the possibilities of more individualised treatment for cancer patients. Maurizio D’Incalci (Mario Negri Institute) presented experimental bases and mechanisms of chemoresistance. Vladimir Lazar (Institut Gustave Roussy) discussed the concept of a comprehensive system biology approach integrating information from different “omics” data sets. Sven Rottenberg (Netherlands Cancer Institute) discussed animal models and insights from a mouse model for hereditary breast cancer in resistance to classical and targeted anti-cancer drugs. Janne Lehtiö and Maria Pernemalm (Karolinska Institutet) discussed the possibilities and challenges of proteomic studies in chemoresistance, with regard to both cellular and plasma or pleural effusion proteomics. Curt Peterson (Linköping University) concluded the experimental session with a presentation on pharmacogenetics and the role for unexpected toxicity in cancer chemotherapy.

In the clinical session, Mark Middleton (Cancer Research UK/Oxford) presented chemoresistance in melanoma, weaknesses in the current therapies and how to define responsiveness/resistance. Marna Bouwhuis (Erasmus University) gave perspectives from the melanoma studies in CHEMORES and evaluation of suggested prognostic factors in IFN-treatment. Jean Charles Soria (Institut Gustave Roussy) discussed DNA repair mechanisms and lung cancer, with focus on ERCC-1 and resistance to cisplatin. Fiona Blackhall (Christie Hospital NHS Trust/University of Manchester) presented perspectives from the lung cancer studies in CHEMORES, gave examples from the clinic and summarized the current literature on genome wide and proteomic studies in lung cancer chemoresistance.

Some speakers have generously agreed to have their presentations available at the CHEMORES web site:







Page updated by Chemores February 12, 2009
Print info: - Tuesday, 27-Jun-2017 00:33:34 CEST
Producerad av Mediabyrån